Startups channel feed – Endpoints News

Startups channel feed

Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes to RNA

8 months ago

Endpoints 11 winner Metsera: Clive Meanwell wagers on obesity after Medicines Company success

8 months ago

Endpoints 11 winner Formation Bio: A Silicon Valley-fueled unicorn aiming to be the next Roivant — or more

8 months ago

Endpoints 11 winner Mirador Therapeutics: Applying precision medicine to immune disease

8 months ago

Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race

8 months ago

Endpoints 11 winner Seaport Therapeutics: The Karuna team is back with another big bet in neuroscience

8 months ago

Insilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter out for second year in a row

8 months ago

ARCH, biotech's star slugger, snags another $3B for 13th fund

8 months ago

Flagship launches startup to design and make lipid nanoparticles for genetic medicines

8 months ago

Barcelona VC firm Asabys raises second fund, adding to Europe’s biotech funding scene

8 months ago

Next-gen obesity biotech BioAge Labs to raise $198M in IPO

8 months ago

Italian gene therapy startup nabs $52M for rare genetic disease that Moderna is working on

8 months ago

Checking up on past Endpoints 11 winners: Who went public, who got bought and who's still working

8 months ago

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

8 months ago

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

8 months ago

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna

8 months ago

Biotech VC firm outlines plans for $100M fund

8 months ago

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

8 months ago

Stem cell startup spun out of George Church’s lab raises $75M

8 months ago

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

8 months ago

Ochre Bio CEO Jack O’Meara steps down, outlines plans for next startup

8 months ago

Biotech IPO market still in flux following flashy Friday tripleheader

8 months ago

Bicara, Zenas and MBX rekindle IPO market with rare Friday tripleheader

8 months ago

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

8 months ago

First page Previous page 9 10 111213 14 15 Next page Last page